Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Illumina Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Illumina Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
The financial ratios over the observed quarters reveal several notable patterns and fluctuations.
- Price to Earnings (P/E) Ratio
- The P/E ratio exhibited an overall upward trend from early 2017 through 2021, starting around 37 and reaching peaks above 100 in late 2020. This indicates increasing market valuations relative to earnings over the period, with significant spikes notably at the end of 2020 and mid-2021. However, toward the latest quarter reported, the ratio declined to approximately 70, suggesting some normalization after elevated valuations.
- Price to Operating Profit (P/OP) Ratio
- This ratio showed considerable variability. Initially, it ranged between approximately 44 and 58, with some fluctuations through 2017 and 2018. Notably, there was a sharp increase starting in late 2020, peaking above 120, which signals a substantial rise in price relative to operating profit. The ratio slightly decreased after this peak but remained significantly higher than in earlier periods, reflecting increased investor expectations or reduced operating profit margins.
- Price to Sales (P/S) Ratio
- The P/S ratio maintained moderate volatility with a gradual upward tendency from about 11 in 2017 to over 22 at the end of 2020. Subsequent quarters saw a reduction back to mid-teens, indicating that the market price relative to sales expanded substantially during the peak period but retreated somewhat afterward. This pattern could reflect growth optimism that partially subsided.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio similarly experienced growth, starting around 10 and peaking near 15 in early 2021. A steep decline followed in the last recorded quarter to 6, which is notably lower than previous values. This sharp drop suggests a significant market reassessment of book value relative to price or possible changes in the company’s equity base or market capitalization. The earlier gradual increase in the P/BV ratio parallels the growth pattern seen in the other valuation metrics.
In summary, all valuation multiples indicated heightened market confidence and valuation expansion through pre-2021 and especially in 2020, followed by varying degrees of correction or stabilization in subsequent quarters. The elevated peaks in late 2020 and early 2021 across different ratios may be attributed to market conditions, company performance expectations, or external factors influencing investor sentiment. The substantial decline in price to book value towards the latest date warrants further investigation to understand underlying causative factors.
Price to Earnings (P/E)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Net income attributable to Illumina stockholders (in millions) | |||||||||||||||||||||||||
| Earnings per share (EPS)2 | |||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/E ratio4 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Data adjusted for splits and stock dividends.
2 Q3 2021 Calculation
EPS
= (Net income attributable to Illumina stockholdersQ3 2021
+ Net income attributable to Illumina stockholdersQ2 2021
+ Net income attributable to Illumina stockholdersQ1 2021
+ Net income attributable to Illumina stockholdersQ4 2020)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Illumina Inc. Quarterly or Annual Report.
4 Q3 2021 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
The analysis of the quarterly financial indicators reveals several trends regarding the company's market valuation and profitability over the observed periods.
- Share Price
- The share price exhibits an overall upward trajectory, starting at $187.14 and reaching peaks of $494.24 and $497.24 during the early and middle parts of 2021. Periodic fluctuations are noticeable, with some declines such as the drop from $355.66 in June 2020 to $292.70 in September 2020, and another decrease after the peaks in 2021. Despite these fluctuations, the long-term trend suggests increasing market confidence and valuation.
- Earnings per Share (EPS)
- EPS values demonstrate variability, initially rising from 5.07 to around 6.82 before declining during mid-2020 to approximately 4.37. Thereafter, EPS recovers partially, reaching 5.80 by the last quarter observed. This pattern suggests some volatility in profitability or earnings recognition, potentially influenced by external factors or company-specific events, but with signs of resilience as EPS rebounds toward the end of the period.
- Price-to-Earnings (P/E) Ratio
- The P/E ratio displays more pronounced fluctuations, increasing sharply from mid-2017 reaching values above 70 during late 2018 and mid-2020. The ratio peaks dramatically at 109.92 in December 2020, indicating that share prices were high relative to earnings at that time. Subsequent quarters maintain elevated P/E ratios, mostly ranging between 70 and 95, before slightly decreasing to 70.41. This elevated valuation relative to earnings may indicate high market expectations for future growth or possibly overvaluation in some periods.
In summary, the share price growth illustrates rising investor demand and optimism, though not consistently smooth. EPS trends reflect fluctuating profitability with partial recovery following a mid-period downturn. The high and variable P/E ratios suggest the market often priced shares at a premium compared to current earnings, which may reflect growth expectations but also increased valuation risk during some periods.
Price to Operating Profit (P/OP)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Income (loss) from operations (in millions) | |||||||||||||||||||||||||
| Operating profit per share2 | |||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/OP ratio4 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Data adjusted for splits and stock dividends.
2 Q3 2021 Calculation
Operating profit per share
= (Income (loss) from operationsQ3 2021
+ Income (loss) from operationsQ2 2021
+ Income (loss) from operationsQ1 2021
+ Income (loss) from operationsQ4 2020)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Illumina Inc. Quarterly or Annual Report.
4 Q3 2021 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
The analysis of the financial data reveals several notable trends in the share price, operating profit per share, and the price-to-operating profit (P/OP) ratio over the periods observed.
- Share Price
- The share price demonstrates a general upward trajectory from April 2017 to October 2021, starting at $187.14 and reaching peaks around $497.24. Notable surges occurred between April 2018 and July 2018, where the price increased from approximately $231.19 to $324.36. Another significant rise is observed between June 2020 and December 2020, with the price moving from $355.66 to $494.24. Some volatility is evident toward the later periods, with fluctuations between $405.54 and $497.24 before declining to $408.14 in the last reported quarter.
- Operating Profit Per Share
- The operating profit per share shows an increasing trend from April 2017 through December 2019, rising from $3.55 to $6.7. This growth indicates improved operational efficiency and profitability during this timeframe. However, from early 2020 onward, operating profit per share exhibits a downward trend, decreasing to a negative value of -$0.2 by October 2021. The decline is particularly steep between September 2020 and October 2021, suggesting operational challenges or extraordinary costs affecting profitability.
- Price-to-Operating Profit (P/OP) Ratio
- The P/OP ratio fluctuates but generally remains within a moderate range during most of the periods, with values mostly between 44 and 60. There is a marked increase starting in December 2020, jumping to 124.33 and remaining elevated above 100 in subsequent periods before the last data point. This escalation in the P/OP ratio alongside falling operating profit per share implies that the market valuation became increasingly detached from current operating profitability. Investors might have been anticipating future growth or pricing in other factors beyond immediate earnings performance.
In summary, while the share price experienced substantial growth accompanied by rising operating profit per share up to late 2019, subsequent quarters show a divergence with declining operating profitability and elevated valuation multiples. This suggests a period of operational difficulties contrasted with optimistic market expectations or other external influences on stock price behavior during the most recent periods.
Price to Sales (P/S)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Revenue (in millions) | |||||||||||||||||||||||||
| Sales per share2 | |||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/S ratio4 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Data adjusted for splits and stock dividends.
2 Q3 2021 Calculation
Sales per share
= (RevenueQ3 2021
+ RevenueQ2 2021
+ RevenueQ1 2021
+ RevenueQ4 2020)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Illumina Inc. Quarterly or Annual Report.
4 Q3 2021 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends over the periods examined.
- Share Price
- The share price experienced an overall upward trajectory from April 2017 to October 2021, rising from approximately $187 to peaks near $497. Throughout this period, there were notable fluctuations, including a substantial increase around mid-2020 to early 2021, reaching nearly $494, followed by a decline, and then another rise towards late 2021. This suggests periods of increased investor confidence as well as some volatility.
- Sales Per Share
- Sales per share steadily increased from $16.61 in early 2017 to around $27.38 by the last quarter of 2021. Growth was consistent with slight variations, indicating stable revenue growth on a per-share basis. This upward trend underscores improving company performance over time in terms of sales generation per share.
- Price-to-Sales (P/S) Ratio
- The P/S ratio exhibited more variability compared to the other metrics. Early ratios hovered around 11 to 12, but there was a peak reaching approximately 22.26 in late 2020 to early 2021, coinciding with the surge in share price. Subsequently, it declined to about 14.9 by late 2021. The elevated P/S ratio periods indicate heightened market valuation relative to sales, suggestive of increased growth expectations or market optimism during those times.
In summary, the financial data show consistent growth in sales per share complemented by a general increase in share price, albeit with episodes of significant volatility. The valuation as measured by the P/S ratio has experienced considerable fluctuations, reflecting shifts in market sentiment and expectations throughout the analyzed quarters.
Price to Book Value (P/BV)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||
| Total Illumina stockholders’ equity (in millions) | |||||||||||||||||||||||||
| Book value per share (BVPS)2 | |||||||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||||||
| P/BV ratio4 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Data adjusted for splits and stock dividends.
2 Q3 2021 Calculation
BVPS = Total Illumina stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Illumina Inc. Quarterly or Annual Report.
4 Q3 2021 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
The analysis of the financial ratios and share price over the reported quarters reveals several notable trends and fluctuations.
- Share Price Trends
- The share price generally exhibited an upward trajectory from early 2017 through mid-2021, increasing from approximately $187 to a peak near $497. Despite this overall growth, there were intermittent periods of decline and volatility. For instance, following the peak in July 2018 at $324.36, prices dipped below $290 in subsequent quarters before resuming an upward trend. A pronounced spike occurred in December 2020, reaching about $494, followed by fluctuations through to October 2021.
- Book Value Per Share (BVPS) Trends
- The book value per share showed a steady and consistent increase throughout the timeframe, growing from $17.47 in April 2017 to $67.77 by October 2021. This steady growth indicates continual accumulation of equity value on a per-share basis, with no observable declines or volatility, suggesting a stable enhancement of the underlying book value.
- Price to Book Value (P/BV) Ratio Trends
- The P/BV ratio, which compares market price to book value, demonstrated significant variability. It began above 10 in early 2017, fluctuating throughout the quarters with notable peaks around July 2018 (14.64) and December 2020 (15.36). These peaks indicate phases where the market price substantially exceeded the book value, potentially reflecting optimistic investor sentiment or expectations. Conversely, the ratio sharply declined to a low of 6.02 by October 2021 despite the highest BVPS recorded, signifying that the share price did not keep pace with the increase in book value during that quarter.
- Insights and Interpretations
- The divergent trends between the steady rise in BVPS and the more volatile share price and P/BV ratio suggest that while the company's intrinsic value was growing continuously, market perceptions and valuations were more reactive and variable. Periods of high P/BV ratios may correspond to heightened investor optimism or market speculation, whereas drops in the ratio imply more conservative market valuation relative to book value. The large increase in book value by late 2021 without a corresponding proportional increase in share price resulted in a decreased valuation multiple, which may indicate a potential re-rating or market adjustment in response to growth expectations or external factors.